A Single-center, Randomized, Double-blind, Placebo-controlled Phase I Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Dose (SAD) Administration of MT1011 Injection in Healthy Subjects
Latest Information Update: 11 Jul 2025
At a glance
- Drugs MT 1011 (Primary)
- Indications Unspecified
- Focus Adverse reactions
- Sponsors Shaanxi Micot Technology Co
Most Recent Events
- 23 Jun 2025 New trial record